Renal impairment in myeloma: negative association with isoelectric point of excreted Bence-Jones protein

A G W NORDEN,* F V FLYNN,* L M FULCHER,* J D M RICHARDS

From the Departments of *Chemical Pathology and Haematology, University College Hospital, London

SUMMARY The isoelectric point (pl) of the major form of Bence-Jones protein excreted by 62 patients with myeloma and six with macroglobulinaemia was measured by combining isoelectric focusing with immunoblotting techniques. The distribution of the pl values for both k and l type proteins was bimodal, most falling in the ranges 5.0–6.0 and 7.0–7.5. Plasma creatinine and creatinine clearance and the urine excretion of α1-microglobulin and β2-microglobulin were measured in 24 of the patients. Those patients, who were free of additional factors known to have an association with the development of renal impairment, were followed up for a mean period of 16 months (range three to 28 months). It was found that renal impairment was not related to the pl of the Bence-Jones protein excreted.

Although the occurrence of Bence-Jones proteinuria in patients with myeloma is strongly associated with renal failure, the development of renal impairment is not predictable, and in some cases Bence-Jones protein may continue to be excreted with minimal renal malfunction. Other features of the disease such as hypercalcaemia, or the use of nephrotoxic drugs, may be responsible for this complication.

It has been proposed that the physical properties of the Bence-Jones protein are important in determining whether renal impairment develops. Thus it has been claimed that Bence-Jones proteins of relatively high isoelectric point (pl) are more likely to be associated with renal impairment than those of low pl and it has been suggested that this might be due to a strong ionic interaction with the acidic Tamm-Horsfall glycoprotein (pl 3.5) or other tubular proteins at the pH occurring within the renal tubule. Such interactions might lead to cast formation or tubulopathy and eventually glomerular failure. The combined evidence from animal models and clinical studies, however, is contradictory.

We recently developed a method, combining isoelectric focusing and immunoblotting, which permits the direct measurement of the pl of Bence-Jones proteins. This new procedure has the major advantage that preliminary concentration, electrophoresis, or liquid chromatography of the urine specimen is unnecessary. Using this technique we investigated the association between the pl values of Bence-Jones proteins and several indices of both glomerular and tubular function.

Patients and methods

Sixty two patients with myeloma and six with macroglobulinaemia were studied. All were excreting Bence-Jones protein and all those with myeloma fulfilled the diagnostic criteria used in the first United Kingdom myelomatosis trial organised by the Medical Research Council. Twenty four patients were studied sequentially in more detail; these were selected by exclusion of those with some additional complicating factor that could predispose to the development of renal impairment, and by eliminating those who had a history of renal disease before developing myeloma. The former exclusions included patients with hypercalcaemia, hyperuricaemia, or hypercalciuria, either before or after rehydration. Those who had begun chemotherapy were also excluded, apart from six who had received a dose well below that reported as causing renal impairment: these six patients had received only one or two of the usual nine courses of a standard regimen which comprised melphalan (0.25 mg/kg/day) and prednisolone (1 mg/kg/day) for four days every six weeks.

The pl of the major Bence-Jones protein excreted, the plasma creatinine and creatinine clearance, and the urinary excretion of α1-microglobulin and β2-microglobulin were measured. The reciprocal of the plasma creatinine concentration change each month and the changes in the urinary excretion of α1-
proteins in 62 patients
three and the
impairment. The
were
used and of
microglobulin
macroglobulinaemia.

patients with
patients
with
myeloma
and six

Open circles refer to patients graded as having a one-plus quantity of Bence-Jones protein and dark circles to patients with two- to three-plus Bence-Jones protein excretion.8

Alpha-1-microglobulin was measured by solid-phase enzyme immunoassay using "Imzyme alpha-1-m" reagents (Diamed Diagnostics Ltd, Bootle, Merseyside). Beta-2-microglobulin was quantitated by the "Beta-2-micro" kit (Pharmacia). Creatinine was determined in plasma by an end point alkaline picrate method using a "SMAC" Analyzer (Technicon Ltd, Basingstoke, Hampshire), and in urine by a rate reaction alkaline picrate method using an "Astra" analyser (Beckman Ltd, High Wycombe, Buckinghamshire).

Results

The frequency distribution of the measured pI values of the major form of Bence-Jones protein excreted by the 68 patients with myeloma or macroglobulinaemia measurement of the pI values of the Bence-Jones proteins were performed as described previously.10,12 Bence-Jones protein excretion was estimated semiquantitatively by applying a volume of urine containing 25 nmol creatinine to the isoelectric focusing gels and using a previously described scoring system.10,12

Two dimensional isoelectric focusing and electrophoresis was carried out using pI 3–10 ampholytes according to Pharmacia Application Note No 52-1464-00-04 (Pharmacia Ltd, Central Milton Keynes, Buckinghamshire). Such gels were immunoblotted as described previously.10

Alpha-1-microglobulin was measured by solid-phase enzyme immunoassay using "Imzyme alpha-1-m" reagents (Diamed Diagnostics Ltd, Bootle, Merseyside). Beta-2-microglobulin was quantitated by the "Beta-2-micro" kit (Pharmacia). Creatinine was determined in plasma by an end point alkaline picrate method using a "SMAC" Analyzer (Technicon Ltd, Basingstoke, Hampshire), and in urine by a rate reaction alkaline picrate method using an "Astra" analyser (Beckman Ltd, High Wycombe, Buckinghamshire).

Results

The frequency distribution of the measured pI values of the major form of Bence-Jones protein excreted by the 68 patients with myeloma or macroglobulinaemia

Materials and Methods

Patients

Norden, Flynn, Fulcher, Richards
is shown in fig 1. This shows a bimodal distribution for both κ and λ type Bence-Jones proteins, with pI values of 5.0–6.0 and 7.0–7.5 being the most common.

In figs 2a and b the plasma creatinine and creatinine clearance values, obtained at the time of presentation in the 24 patients lacking an additional recognised cause for renal impairment, are shown plotted against the pI values of the corresponding Bence-Jones proteins. These show no correlation between the variables, regardless of the quantity of Bence-Jones protein being excreted.

In fig 3 the quantities of α-1-microglobulin excreted by the 24 patients lacking an additional recognised cause for renal impairment are shown plotted against the pI values of the major Bence-Jones protein excreted. This shows no correlation between the two measurements. Absence of any correlation was also found when patients with plasma creatinine concentrations greater than 200 μmol/l were omitted. A similar negative finding was obtained in relation to the quantity of β-2-microglobulin being excreted.

When the rate of change in the reciprocal of the plasma creatinine and in the excretion of α-1- and β-2-microglobulins was examined in relation to the pI values of the Bence-Jones proteins, no significant correlations were detected.

When we measured the electrophoretic mobility of eight Bence-Jones proteins over a pH gradient, using isoelectric focusing and electrophoresis performed at right angles to one another (fig 4), we found a good correlation between the electrophoretic mobility of the proteins at pH 6 and the pI of the protein (fig 5).

**Discussion**

There have been two previous studies of the association between the pI of Bence-Jones proteins and the development of renal impairment in patients with myeloma. Coward et al found that the occurrence of Bence-Jones protein with a high pI had a definite correlation with reduced creatinine clearance. More recently, Johns et al reported that proximal tubular function, as measured by the urinary α-1-microglobulin content, was more severely impaired in patients excreting Bence-Jones protein of high pI value, but that there was no association with the serum creatinine concentration. We have not confirmed either of the positive associations reported in these studies. It may be important that both these groups of authors used less direct approaches to pI measurement than ourselves; nevertheless, it is unlikely that electrophoresis after preliminary concentration of the urine or fast protein liquid chromatography would bias the pI measurements in relation to the presence or absence of renal impairment. It is more likely that different criteria used for the selection of patients, unsuspected heterogeneity in the aetiology of renal impairment, or chance bias in population sampling contributed to the different findings.

In the context of the possible nephrotoxicity of some Bence-Jones proteins three criticisms of the relevance of in vitro pI measurements are apparent. First, the pI is not the critical variable in a charge-related hypothesis of nephrotoxicity; it is net charge at the pH prevailing at the site of toxicity that should matter. Nevertheless, some difference in nephrotoxicity ought to be seen between Bence-Jones proteins with pIs within or above the physiological limits of in-vivo pH. Secondly, the association between pI values measured in agarose gels containing ampholytes and those
prevailing in the kidney is unknown. Thirdly, it is uncertain whether charge interactions between Bence-Jones proteins and renal tissue or urine constituents will be clinically important at the pH values and ionic strengths prevailing within the renal tubule.

We measured electrophoretic mobility at pH 6 to provide an indication of the charge carried by Bence-Jones proteins. The good correlation we found between this mobility and the pI of the proteins suggests that the pI provides a good measure of net charge at a physiological pH and that pI measurements are relevant to the testing of a charge-based hypothesis of the nephrotoxicity of Bence-Jones proteins. In this context it is of interest that Hill et al found that there was an excellent correlation between decreasing electrophoretic mobility of the light chain protein excreted and increasing serum urea concentration among 17 patients with myeloma and Bence-Jones proteinuria. This association was attributed to the effects of the charge of the molecule on either its polymerisation or the quantity that could be filtered at the glomerulus. Unfortunately, the pH at which they measured the electrophoretic mobility of the light chains was not specified.

A fundamental difficulty complicating the interpretation of all the studies that have attempted to relate the charge on Bence-Jones proteins to nephrotoxicity is that the quantity of Bence-Jones protein reaching the renal tubule is unknown. As has been pointed out by Rosansky et al it is not valid to assume that the amount excreted can be directly related to the quantity entering the glomerular filtrate.

Interest in the pI of Bence-Jones proteins was stimulated by in vitro studies of nephrotoxicity. Other investigations, such as those of light chain polymerisation, have failed to show physical properties which might affect nephrotoxicity. If physical characterisation of Bence-Jones proteins permitted the identification of a subgroup of patients at particular risk of developing renal impairment, such patients could be given intensive prophylaxis. A study such as this cannot prove that the net charge on a Bence-Jones protein is unimportant in the processes which underlie renal impairment, but our findings do suggest that the pI of the protein is a poor clinical guide.

This work was supported by a grant from the locally organised research scheme of the North East Thames Regional Health Authority. We also thank the many clinicians who permitted us to study their patients.

References


Requests for reprints to: Professor FW Flynn, Department of Chemical Pathology, University College Hospital, Gower Street, London WC1E 6AU, England.